DENVER, Feb. 22, 2023 /CNW/ – Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share…

Source

Previous articleWebinar – Integrative Harm Reduction Psychotherapy (IHRP) Rationale, Theory and Technique
Next articleTranscend Therapeutics announces Series A funding round of $40 million